BET-inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

BET-inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is caused by frequent relapses and acquired resistance. Despite that several target-based approaches with potential therapeutic impact on SCLC have been identified, numerous targeted drugs have not been succe...

Full description

Bibliographic Details
Main Authors: Francesco Paolo Fiorentino, Irene Marchesi, Christoph Schröder, Ronny Schmidt, Jun Yokota, Luigi Bagella
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:International Journal of Molecular Sciences
Subjects:
SCLC
BET
PARP
BMN673
GSK-525762A
Online Access:https://www.mdpi.com/1422-0067/21/24/9595

Similar Items

Similar Items